Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Werewolf Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
HOWL
Nasdaq
8731
https://werewolftx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Werewolf Therapeutics Inc
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Apr 24th, 2024 2:05 pm
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
- Apr 23rd, 2024 12:00 pm
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
- Apr 15th, 2024 4:00 pm
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
- Apr 5th, 2024 8:30 pm
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
- Apr 4th, 2024 8:30 pm
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
- Mar 12th, 2024 1:55 pm
Werewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
- Mar 9th, 2024 1:50 pm
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
- Mar 7th, 2024 1:45 pm
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 7th, 2024 12:00 pm
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
- Mar 6th, 2024 1:00 pm
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
- Mar 5th, 2024 9:30 pm
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
- Jan 8th, 2024 12:00 pm
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
- Jan 4th, 2024 9:05 pm
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
- Dec 14th, 2023 10:04 am
Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$14m last week but private equity firms profited the most
- Dec 7th, 2023 10:33 am
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
- Nov 22nd, 2023 12:00 pm
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 14th, 2023 9:25 pm
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Nov 3rd, 2023 11:00 am
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Oct 31st, 2023 1:00 pm
Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?
- Oct 27th, 2023 8:58 am
Scroll